Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Neonatology|July 12, 2018
Risk Factors for Necrotizing Enterocolitis: A Prospective Multicenter Case-Control StudyDaniel J C Berkhout, Patrick Klaassen, Hendrik J Niemarkt, et al.
Antibiotics (Basel, Switzerland)|June 28, 2023
Duration of Neonatal Antibiotic Exposure in Preterm Infants in Association with Health and Developmental Outcomes in Early ChildhoodNancy Deianova, Nanne K de Boer, Hafsa Aoulad Ahajan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 9, 2021
Profound Pathogen-Specific Alterations in Intestinal Microbiota Composition Precede Late-Onset Sepsis in Preterm Infants: A Longitudinal, Multicenter, Case-Control StudySofia El Manouni El Hassani, Hendrik J Niemarkt, Daniel J C Berkhout, et al.
Neurology|June 5, 2016
Gallbladder and the risk of polyps and carcinoma in metachromatic leukodystrophyDiane F van Rappard, Marianna Bugiani, Jaap J Boelens, et al.
Neonatology|April 5, 2019
Risk Factors for Late-Onset Sepsis in Preterm Infants: A Multicenter Case-Control StudySofia El Manouni El Hassani, Daniel J C Berkhout, Hendrik J Niemarkt, et al.
Alimentary Pharmacology & Therapeutics|October 18, 2024
Faecal Volatile Organic Compounds to Detect Colorectal Neoplasia in Lynch Syndrome-A Prospective Longitudinal Multicentre StudyElsa L S A van Liere, Dewkoemar Ramsoekh, Emma Daulton, et al.
European Journal of Pediatrics|December 3, 2020
Predictive factors for surgical treatment in preterm neonates with necrotizing enterocolitis: a multicenter case-control studySofia El Manouni El Hassani, Hendrik J Niemarkt, Joep P M Derikx, et al.
European Journal of Pediatrics|August 4, 2022
Association between duration of early empiric antibiotics and necrotizing enterocolitis and late-onset sepsis in preterm infants: a multicenter cohort studyThomas H Dierikx, Nancy Deianova, Jip Groen, et al.
Alimentary Pharmacology & Therapeutics|April 22, 2024
Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's diseaseStephanie A Vuijk, Maria M E Jongsma, Britt M Hoeven, et al.
The Lancet. Infectious Diseases|April 16, 2023
Redefining Clostridioides difficile infection antibiotic response and clinical outcomesAnne J Gonzales-Luna, Andrew M Skinner, Carolyn D Alonso, et al.
Pageof 12